Guardant Health, Inc. (GH) · Nov 3, 2026 · Other events

Guardant Health grants co-CEOs 465,413 TSR-based PSUs

465,413 PSU grant — 116,353 three-year PSUs plus 349,060 five-year PSUs; maximum payout 250% of target

Guardant Health’s executive compensation filing grants its co-CEOs 465,413 target PSUs tied to three- and five-year relative TSR.

Guardant Health is in a rapid commercialization phase: its oncology and Shield screening businesses were driving 44% second-quarter revenue growth, while management raised 2026 revenue guidance to $1.34–$1.36 billion. This filing does not change that operating story. It is an executive-compensation grant to co-CEOs Helmy Eltoukhy and AmirAli Talasaz, not a new product, forecast, financing, or leadership change. The filing states that each PSU represents the right to receive one share, subject to vesting. 〔0〕

The award is designed to keep both founders tied to long-term shareholder performance. The 465,413 target PSUs are split between 116,353 three-year awards and 349,060 five-year awards, with vesting based on Guardant’s total shareholder return relative to an S&P 500 peer group. 〔1〕 At target, the grant equals roughly 0.35% of Guardant’s approximately 134.2 million shares outstanding as of July 24, 2026; at the maximum 250% payout, it could represent roughly 0.87%.

The main tension is alignment versus potential dilution, not business execution. The performance hurdle is meaningful—below the 40th percentile earns nothing, while the maximum requires at least the 90th percentile—but even a negative absolute TSR outcome can still permit up to 100% of target for each tranche. The filing also leaves the grant date and participant name as blanks in the supplied exhibit, so the exact effective date and finalized individual allocation are not clear from this document.

Bottom line: This is a long-term retention and incentive action for Guardant’s two founders, broadly consistent with an expected annual compensation cycle. It reinforces alignment but does not materially advance or weaken the company’s underlying growth story today.

What to watch next

Q3 2026 earnings report, November 5

Original filing on SEC EDGAR

Guardant Health grants co-CEOs 465,413 TSR-based PSUs | GH Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.